Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 Mar 2023
A new study by Diego Adão and team has shown that using erythromycin before the exam can improve your ability to see your vision.
Read Full NewsPain that interferes with daily functioning is associated with higher odds of frailty and its progression in adult survivors of childhood cancer.
Cancer care is becoming too complex for any one clinician to track alone, making AI an increasingly valuable tool in modern oncology.
New data with longer-term follow-up suggest that PSA screening probably lowers prostate cancer mortality — but experts stress the gains are modest and come with risk for overdiagnosis.
The CAPItello-281 trial reported a 19% improvement in radiographic progression-free survival.
1.
Most NMIBC Recurrences Seen in BCG-Exposed Patients
2.
Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC
3.
Novel radiotracer identifies biomarker for triple-negative breast cancer
4.
The standard for high-risk prostate cancer is supported by a study using high-dose RT and long-term ADT.
5.
Accuracy of Skin Cancer Diagnosis Varies by Physician, Exam Method
1.
Subchorionic Hematoma: Causes, Symptoms, and Treatment
2.
Early Detection of Breast Cancer: Signs, Symptoms, and Screening Methods
3.
Advanced Practices in Hematology in Daily Practice
4.
Polycythemia Vera: A Historical Perspective and Contemporary Management
5.
PARP Inhibitors in Testicular Cancer: Tackling Cisplatin Resistance with Precision
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
2.
From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD
3.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
5.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge